Literature DB >> 28547036

Circulating microRNA-1a is a biomarker of Graves' disease patients with atrial fibrillation.

Fang Wang1, Sheng-Jie Zhang2, Xuan Yao2, Dong-Mei Tian1, Ke-Qin Zhang3, Dun-Min She3, Fei-Fan Guo4, Qi-Wei Zhai4, Hao Ying2, Ying Xue5.   

Abstract

PURPOSE: It has been increasingly suggested that specific microRNAs expression profiles in the circulation and atrial tissue are associated with the susceptibility to atrial fibrillation. Nonetheless, the role of circulating microRNAs in Graves' disease patients with atrial fibrillation has not yet been well described. The objective of the study was to identify the role of circulating microRNAs as specific biomarkers for the diagnosis of Graves' disease with atrial fibrillation.
METHODS: The expression profiles of eight serum microRNAs, which are found to be critical in the pathogenesis of atrial fibrillation, were determined in patients with Graves' disease with or without atrial fibrillation. MicroRNA expression analysis was performed by real-time PCR in normal control subjects (NC; n = 17), patients with Graves' disease without atrial fibrillation (GD; n = 29), patients with Graves' disease with atrial fibrillation (GD + AF; n = 14), and euthyroid patients with atrial fibrillation (AF; n = 22).
RESULTS: Three of the eight serum microRNAs,i.e., miR-1a, miR-26a, and miR-133, had significantly different expression profiles among the four groups. Spearman's correlation analysis showed that the relative expression level of miR-1a was positively correlated with free triiodothyronine (FT3) and free thyroxine (FT4), and negatively related to thyroid stimulating hormone. Spearman's correlations analysis also revealed that the level of miR-1a was negatively correlated with a critical echocardiographic parameter (left atrial diameter), which was dramatically increased in GD + AF group compared to GD group. Furthermore, the receiver-operating characteristic curve analysis indicated that, among the eight microRNAs, miR-1a had the largest area under the receiver-operating characteristic curves not only for discriminating between individuals with and without Graves' disease, but also for predicting the presence of atrial fibrillation in patients with Graves' disease.
CONCLUSIONS: Our findings showed that the levels of serum miR-1a were significantly decreased in GD + AF group compared with GD group, suggesting that serum miR-1a might serve as a novel biomarker for diagnosis of atrial fibrillation in patients with Graves' disease.

Entities:  

Keywords:  Atrial fibrillation; Graves’ disease; MicroRNA; Thyroid hormone

Mesh:

Substances:

Year:  2017        PMID: 28547036     DOI: 10.1007/s12020-017-1331-4

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  49 in total

1.  Plasma microRNAs are associated with atrial fibrillation and change after catheter ablation (the miRhythm study).

Authors:  David D McManus; Kahraman Tanriverdi; Honghuang Lin; Nada Esa; Menhel Kinno; Divakar Mandapati; Stanley Tam; Okike N Okike; Patrick T Ellinor; John F Keaney; J Kevin Donahue; Emelia J Benjamin; Jane E Freedman
Journal:  Heart Rhythm       Date:  2014-10-09       Impact factor: 6.343

2.  Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus.

Authors:  Honglei Wang; Wujian Peng; Xin Ouyang; Wuxian Li; Yong Dai
Journal:  Transl Res       Date:  2012-05-04       Impact factor: 7.012

3.  Role of miR-21 in the pathogenesis of atrial fibrosis.

Authors:  Oliver Adam; Björn Löhfelm; Thomas Thum; Shashi K Gupta; Sarah-Lena Puhl; Hans-Joachim Schäfers; Michael Böhm; Ulrich Laufs
Journal:  Basic Res Cardiol       Date:  2012-07-04       Impact factor: 17.165

Review 4.  Biochemical basis of thyroid hormone action in the heart.

Authors:  W H Dillmann
Journal:  Am J Med       Date:  1990-06       Impact factor: 4.965

5.  Changes of serum Mir-217 and the correlation with the severity in type 2 diabetes patients with different stages of diabetic kidney disease.

Authors:  Ying Shao; Huiwen Ren; Chuan Lv; Xiaoyu Ma; Can Wu; Qiuyue Wang
Journal:  Endocrine       Date:  2016-08-13       Impact factor: 3.633

6.  MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation.

Authors:  Kristin Dawson; Reza Wakili; Balázs Ordög; Sebastian Clauss; Yu Chen; Yuki Iwasaki; Niels Voigt; Xiao Yan Qi; Moritz F Sinner; Dobromir Dobrev; Stefan Kääb; Stanley Nattel
Journal:  Circulation       Date:  2013-03-04       Impact factor: 29.690

7.  miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2.

Authors:  Dmitry Terentyev; Andriy E Belevych; Radmila Terentyeva; Mickey M Martin; Geraldine E Malana; Donald E Kuhn; Maha Abdellatif; David S Feldman; Terry S Elton; Sandor Györke
Journal:  Circ Res       Date:  2009-01-08       Impact factor: 17.367

8.  Expression profiles of six circulating microRNAs critical to atherosclerosis in patients with subclinical hypothyroidism: a clinical study.

Authors:  Xinhuan Zhang; Shanshan Shao; Houfa Geng; Yong Yu; Chenggang Wang; Zhanfeng Liu; Chunxiao Yu; Xiuyun Jiang; Yangxin Deng; Ling Gao; Jiajun Zhao
Journal:  J Clin Endocrinol Metab       Date:  2014-02-11       Impact factor: 5.958

9.  MicroRNA-1 accelerates the shortening of atrial effective refractory period by regulating KCNE1 and KCNB2 expression: an atrial tachypacing rabbit model.

Authors:  Xiaomeng Jia; Shaohua Zheng; Xinxing Xie; Yujiao Zhang; Weizong Wang; Zhongsu Wang; Yong Zhang; Jiangrong Wang; Mei Gao; Yinglong Hou
Journal:  PLoS One       Date:  2013-12-30       Impact factor: 3.240

10.  Circulating MicroRNAs Characterizing Patients with Insufficient Coronary Collateral Artery Function.

Authors:  Nazanin Hakimzadeh; A Yaël Nossent; Anja M van der Laan; Stephan H Schirmer; Maurice W J de Ronde; Sara-Joan Pinto-Sietsma; Niels van Royen; Paul H A Quax; Imo E Hoefer; Jan J Piek
Journal:  PLoS One       Date:  2015-09-02       Impact factor: 3.240

View more
  5 in total

1.  Circulating microRNA-144-3p and miR-762 are novel biomarkers of Graves' disease.

Authors:  Qiuming Yao; Xuan Wang; Weiwei He; Zhenyu Song; Bin Wang; Jinan Zhang; Qiu Qin
Journal:  Endocrine       Date:  2019-04-04       Impact factor: 3.633

2.  Exosomal microRNA-29a mediates cardiac dysfunction and mitochondrial inactivity in obesity-related cardiomyopathy.

Authors:  Fengqin Li; Kuikui Zhang; Ting Xu; Wenjuan Du; Bo Yu; Youbin Liu; Honggang Nie
Journal:  Endocrine       Date:  2018-09-27       Impact factor: 3.633

3.  MicroRNA expression signatures of atrial fibrillation: The critical systematic review and bioinformatics analysis.

Authors:  Nan-Nan Shen; Chi Zhang; Zheng Li; Ling-Cong Kong; Xin-Hua Wang; Zhi-Chun Gu; Jia-Liang Wang
Journal:  Exp Biol Med (Maywood)       Date:  2019-11-25

4.  Biomarkers in the clinical management of patients with atrial fibrillation and heart failure.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Mark Ainslie; Virginia Mplani; Georgia Karavasili; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-11-28       Impact factor: 3.327

5.  miR-199a Downregulation as a Driver of the NOX4/HIF-1α/VEGF-A Pathway in Thyroid and Orbital Adipose Tissues from Graves' Patients.

Authors:  Julie Craps; Virginie Joris; Lelio Baldeschi; Chantal Daumerie; Alessandra Camboni; Antoine Buemi; Benoit Lengelé; Catherine Behets; Antonella Boschi; Michel Mourad; Marie-Christine Many; Chantal Dessy
Journal:  Int J Mol Sci       Date:  2021-12-23       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.